votoplam
votoplam: developed by 1 company · 1 clinical trial tracked.
votoplam evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect votoplam to PTCT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could votoplam → PTCT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 1 study sponsors
Related indications
Huntington's disease (HD)Huntington Disease
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| PTC THERAPEUTICS, INC. (PTCT) Huntington's disease (HD) | Phase 2 |
Clinical Trials (1)
A Randomized, Placebo-controlled, Double-blind Phase 3 Study to Evaluate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Primary endpoint: Change from Baseline in cUHDRS score
InterventionalRandomizedquadruple770 targetStarted 2026-03Completion 2030-0450 sites · Argentina, Australia, Belgium, Canada…Novartis Pharmaceuticals
Frequently asked questions
Who is developing votoplam?
votoplam is being developed by PTC THERAPEUTICS, INC..
How many clinical trials involve votoplam?
BioSniper tracks 1 clinical trial involving votoplam.